Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Insulin Dependent Clear all
Completed Not applicable Interventional Results available

Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes

NCT02033499
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
SMBG
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 9, 2026, 1:51 AM EDT
Enrolling by invitation Not applicable Interventional

T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking

NCT07422831
View directory record Official record
Conditions
Type 2 Diabetes, Non Insulin Dependent Diabetes
Interventions
Periodic, over-the-counter continuous glucose monitoring
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glimepiride
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Sep 9, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional

ED Diabetes Screening and Outpatient Care - Aim 3

NCT05899023
View directory record Official record
Conditions
Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
Interventions
Telehealth Bridge Visits, Standard of Care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

NCT00071422
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
INGAP-Peptide, placebo
Drug
Lead sponsor
Exsulin Corporation
Industry
Eligibility
35 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
17
States / cities
La Jolla, California • San Diego, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00035984
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
100
States / cities
Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Effects of Vitamin C on Patients With Type 2 Diabetes

NCT00001870
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin Dependent, Non-Insulin Dependent
Interventions
Acetylcholine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Neoantigen Cancer Vaccine

NCT03639714
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
Interventions
GRT-C901, GRT-R902, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 9, 2026, 1:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01105429
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
BMS-820132, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

NCT00642278
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions
Canagliflozin (JNJ-28431754), Sitagliptin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Mulberry Leaf on Type 2 Diabetes

NCT00795704
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mulberry Leaf Extract, Placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 4 Interventional

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

NCT00035568
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), or Metformin HCl alone, or Glyburide alone.
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

NCT00237640
View directory record Official record
Conditions
Diabetes Mellitus, Adult Onset
Interventions
Cinnamon or placebo 500 mg capsule twice daily
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

NCT00952991
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
LAF237 = vildagliptin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 9, 2026, 1:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation and Comparison of Noninvasive Blood Glucose Concentrations

NCT01745900
View directory record Official record
Conditions
Insulin Dependent Diabetes, Non Insulin Dependent Diabetes, Gestational Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 9, 2026, 1:51 AM EDT